ENDRA Life Sciences Inc. (NDRA)
NASDAQ: NDRA · Real-Time Price · USD
5.96
+0.46 (8.36%)
At close: Dec 5, 2025, 4:00 PM EST
5.95
-0.01 (-0.17%)
After-hours: Dec 5, 2025, 7:38 PM EST
Company Description
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound.
The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source comprising radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
ENDRA Life Sciences Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | May 9, 2017 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Alexander Tokman |
Contact Details
Address: 3600 Green Court, Suite 350 Ann Arbor, Michigan 48105-1570 United States | |
| Phone | 734 335 0468 |
| Website | endrainc.com |
Stock Details
| Ticker Symbol | NDRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001681682 |
| CUSIP Number | 29273B104 |
| ISIN Number | US29273B5003 |
| Employer ID | 26-0579295 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Alexander Y. Tokman | Chief Executive Officer and Chairman |
| Richard Jacroux | Chief Financial Officer and Secretary |
| Michael Thornton Ph.D. | Chief Technology Officer |
| Dr. Jonathan Behr Ph.D. | Co-Founder |
| Scott Sober | Head of Operations |
| Ziad Rouag | Head of Regulatory and Clinical Affairs |
| Idan Steinberg | Head of Engineering |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 28, 2025 | 8-K | Current Report |
| Nov 26, 2025 | SCHEDULE 13D | Filing |
| Nov 26, 2025 | 424B4 | Prospectus |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | 8-K | Current Report |
| Nov 14, 2025 | 10-Q | Quarterly Report |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 6, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Oct 30, 2025 | SCHEDULE 13G | Filing |
| Oct 30, 2025 | 8-K | Current Report |